Pregabalin is an effective treatment for patients who experience below-level neuropathic pain following a spinal cord injury, according to data presented at the American Pain Society's 31st Annual Scientific Meeting.
Severity of sleep disturbance in patients with painful diabetic peripheral neuropathy (DPN) or post-herpetic neuralgia (PHN) may be predictive of patient response to pregabalin treatment for neuropathic pain reduction, a presentation at the American Pain Society's 31st Annual Scientific Meeting has found.
The percentage of patients in community-practice settings who newly initiate opioid therapy while taking gabapentin and pregabalin for postherpetic neuralgia suggest these agents should be titrated to higher and potentially more effective dosages, a study presented at the American Pain Society's 31st Annual Scientific Meeting has found.
Patients with diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN) treated with pregabalin have rapid, significant, and sustained improvement in sleep, according to a posthoc analysis of 16 placebo-controlled trials of pregabalin in 4,527 patients reported during the American Pain Society's 31st Annual Scientific Meeting.
May 01, 2012
Pain catastrophizing, in particular ruminating about pain, has an indirect effect on clinical pain severity and pain-related interference, through sleep disturbance.